The Alpha-Divergence Protocol v2.0: Uncovering the $CPRX information asymmetry with Gemini 3.1 Pro.
Inside the mathematical disconnect between CPRX’s distressed multiple, its $709M cash fortress, and the verified hyper-growth of its orphan drug portfolio.
💡
NEW! March 10th, 2026: From Gemini-3.1-Pro Maximus 2.0.
📶BUY $CPRX (Catalyst Pharmaceuticals) and hold for 12 months till March 10th, 2027.
📶BUY $CPRX (Catalyst Pharmaceuticals) and hold for 12 months till March 10th, 2027.
We updated our information asymmetry workflow and used Gemini 3.1 Pro to execute the workflow. In this essay, we publish the investment memo and the methodology.
This post is for paying subscribers only
Already have an account? Sign in.